WBCIL Clinches National Intellectual Property Award 2024 for Excellence in Patents and Innovation
March 26, 2025, marked a historic day for West Bengal Chemical Industries Limited (WBCIL) as it was honored with the prestigious National Intellectual Property (IP) Award 2024, conferred by the Ministry of Commerce & Industry, Government of India. The award was presented at the iconic Bharat Mandapam, New Delhi, amidst the esteemed presence of Hon’ble Minister Mr. Piyush Goyal, Hon’ble Justice Pratibha M. Singh of the Delhi High Court, and leading policymakers, innovators, and business leaders of India.
This award is a monumental achievement for WBCIL, recognizing the company as the “Top Indian MSME for Patent Filing, Grant & Commercialization”—a testament to its sustained efforts in developing cutting-edge, patent-driven solutions that are already making an impact across the pharmaceutical, nutraceutical, and cosmeceutical industries.
🥇 The Journey Behind the Award: WBCIL’s Innovation-Driven DNA
Founded in 1962, WBCIL has always believed that the key to industrial and healthcare progress is innovation rooted in scientific research. Over the decades, the company has evolved from being a reputed Active Pharmaceutical Ingredient (API) manufacturer to becoming a leader in liposome technology and nutraceutical innovations. The National IP Award 2024 celebrates WBCIL’s contributions in building a strong IP portfolio while successfully translating patents into commercially viable products. In an era where intellectual property is considered the backbone of industrial competitiveness, WBCIL has proven its mettle.
West Bengal Chemical Industries Limited (WBCIL) has proudly earned the National Intellectual Property Award 2024 in the category of “Top Indian MSME for Patent Filing, Grant & Commercialization”. This recognition, presented by the Ministry of Commerce & Industry, Government of India, is a reflection of WBCIL’s relentless pursuit of innovation and IP excellence. The award was conferred on March 26, 2025, at the esteemed Bharat Mandapam, New Delhi, in the presence of Hon’ble Minister Mr. Piyush Goyal and Hon’ble Justice Pratibha M. Singh of the Delhi High Court. The event gathered the most distinguished personalities from India’s innovation, R&D, and IP ecosystem.
WBCIL’s IP Strength: Numbers That Speak Volumes
WBCIL’s National Intellectual Property Award’ journey is driven by the vision of delivering science-backed wellness globally. The company has:
-
Filed 15 patents related to APIs, mineral formulations, and novel nutraceuticals.
-
Secured over 9 patents that are successfully granted and recognized under multiple jurisdictions.
-
Commercialized multiple patented technologies across India and international markets.
-
Continuously invested in in-house R&D, resulting in the development of high-bioavailability APIs with unique delivery systems.
🥇 Why This National Intellectual Property Award Matters?
In a competitive pharmaceutical and nutraceutical landscape, innovation is no longer optional—it is essential. The IP Award acknowledges that WBCIL has not only excelled in filing patents but also achieved successful commercialization, which is often the most challenging phase for MSMEs. By ensuring that its innovations are market-ready and deliver real-world impact, WBCIL is setting a new benchmark for Indian manufacturers, particularly in the MSME sector.
This recognition reflects the contribution of WBCIL’s R&D, Intellectual Property (IP), and Quality Control teams whose combined efforts have helped build an IP portfolio that is not just strong on paper but effective in solving real-world challenges in drug delivery, therapeutic bioavailability, and patient-centric formulations.
A Testament to Leadership and Teamwork
WBCIL attributes this milestone to the visionary leadership of its Managing Director, the scientific acumen of its research teams, and the dedication of every employee who contributed to the company’s innovation journey. The management’s foresight has ensured continuous investment in intellectual property development, state-of-the-art laboratories, and GMP-certified manufacturing units.
Through collaborations with global nutraceutical and pharmaceutical partners, WBCIL has also promoted the internationalization of Indian patents, strengthening India’s IP standing in global markets.
West Bengal Chemical Industries Limited (WBCIL) proudly announces another milestone on its journey towards global pharmaceutical excellence. WBCIL has been officially awarded the prestigious Certificate of Pharmaceutical Product (CPP), affirming its compliance with international regulatory and quality standards for the export of pharmaceutical products.
The CPP, issued under the WHO’s certification scheme, serves as a globally accepted proof that WBCIL’s pharmaceutical products meet stringent requirements for safety, efficacy, and quality. This recognition not only authorizes the export of WBCIL’s APIs to regulated markets but also cements WBCIL’s position as a trusted name in the global pharmaceutical supply chain. The certificate ensures that WBCIL’s APIs are eligible for importation and marketing in multiple countries across diverse regulatory frameworks.
Strengthening WBCIL’s Global Business Capabilities
With this certificate, WBCIL is better positioned to serve its expanding international clientele by:
-
Facilitating faster regulatory approvals in importing countries.
-
Gaining enhanced credibility with global pharmaceutical companies.
-
Boosting the export of high-quality APIs to advanced and emerging markets.
-
Supporting B2B collaborations worldwide.
WBCIL’s Robust Patent Portfolio: 9 Granted Patents
In addition to this export recognition, WBCIL is a proud patent certificate holder for 9 innovative molecules, further reflecting its commitment to R&D, innovation, and intellectual property creation. These patents represent years of scientific dedication and technical excellence:
-
Improved Ferric Carboxymaltose – Designed with reduced side effects and obtained through a cost-effective process.
-
Ferric Maltol – Development of novel polymorphic forms (‘Form S’) with a scalable and stable manufacturing process.
A Step Closer to Global Leadership
This combined achievement of securing CPP certification and holding multiple granted patents underlines WBCIL’s unwavering commitment to scientific integrity, innovation, and international best practices. These advancements ensure that WBCIL’s iron APIs, fertility APIs, and other specialty molecules are well-positioned to meet the dynamic needs of the global pharmaceutical industry.
At WBCIL, we continue to invest in high-quality API manufacturing, intellectual property development, and regulatory excellence, aligning with our mission to “Empower Healthcare, Globally.”
Aligning with India’s Vision of Innovation-Led Growth
This recognition comes at a time when India is advancing towards becoming a global leader in healthcare, biotechnology, and pharmaceutical innovation under the vision of Viksit Bharat. The Government’s thrust on Atmanirbhar Bharat and IPR facilitation has created an encouraging ecosystem, and WBCIL is proud to be an active contributor to this transformation.
The National Intellectual Property Award organized by DPIIT and CGPDTM are among India’s most prestigious honors, focusing on strengthening India’s IP system and inspiring Indian industries to invest in intellectual property as a competitive advantage.
What’s Next for WBCIL?
WBCIL’s focus now is to continue expanding its portfolio of patented APIs and develop:
-
New-generation liposomal APIs.
-
Customized B2B formulations for partners across pharmaceuticals, nutraceuticals, and personal care.
-
Therapeutically validated and clinically backed products.
-
Sustainable and eco-friendly manufacturing practices while maintaining scientific excellence.
As the company sets its sights on expanding into new therapeutic categories and international collaborations, this award is both an inspiration and a responsibility to continue raising the bar.
WBCIL’s Message
We dedicate this achievement to all our team members, clients, scientific collaborators, and regulatory partners who have been part of this journey. The National Intellectual Property Award 2024 strengthens our resolve to pioneer science, serve the global community, and foster a strong culture of intellectual property creation.